Overall, our study confirms the inhibitory effect of MEG3 in ovarian cancer and reveals new regulatory mechanisms of MEG3 from the perspectives of m6A methylation and ceRNA, and our results are expected to provide new targets for the treatment of ovarian cancer. This evidence concerns the gene MEG3 and ovarian carcinoma.